Document:

Document

Exhibit 10.1.2
LICENSE AGREEMENT AMENDMENT
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its Inhibitors in Immuno-regulation (MCG case # 007-98, 011-98, 011-02, 003-03, 009-03) dated September 13, 2005;
and
Inasmuch as the parties agree that the License Agreement contains a provision (Section 4.1) for the acquisition of new, related Improvement Technologies by NewLink arising at MCGRI after the Agreement was signed
and
Inasmuch as NewLink has reviewed a new Improvement Technology (MCG case # 005- 06:  CpG Oligonucleotides Induce Spleen Cells to Acquire IDO-dependent Regulatory Functions, by D. Munn and A. Mellor), and wishes to exercise its option to incorporate those technologies into the existing License Agreement technology portfolio under its standard royalty terms and use conditions,
It is Agreed:
That the parties amend the License Agreement relative to its Exhibit A , such that MCG case #005-06 is to be included in the technology portfolio for development and commercialization by NewLink, effective the date that the License Fee of $20,000 is received at MCGRI.
This present amendment shall hereby be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.

						
	MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE

	NEWLINK GENETICS

	By /s/Betty Aldridge
Name: Betty Aldridge
Title: Executive Director
Date: 4/27/06
	By: /s/Nicholas N. Vahanian
Name: Nicholas N. Vahanian
Title: Chief Medical and Operations Office
Date: 4/21/06Document

Exhibit 10.1.3

LICENSE AGREEMENT AMENDMENT

Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its Inhibitors in Immuno-regulation (MCG case # 007-98, 011-98, 011-02, 003-03, 009-03) dated September 13, 2005;
and
Inasmuch as the parties agree that the License Agreement contains a provision (Section 4.1) for the acquisition of new, related Improvement Technologies by NewLink arising at MCGRI after the Agreement was signed
and
Inasmuch as the NewLink has reviewed a new Improvement Technology (MCG case # 023-07:Synergy Between IDO Inhibitors and PD-1/PD-Ligand Antibodies, by A. Mellor, D. Munn, B. Blazar, and Madhav Sharma; jointly owned with the University of Minnesota), and wishes to exercise its option to incorporate this technology into the existing License Agreement technology portfolio under its standard royalty terms and use conditions,
It is Agreed:
That the parties amend the License Agreement relative to its Exhibit A , such that MCG case # 023-07 is to be included in the technology portfolio for development and commercialization by NewLink, effective the date that the License Fee of $20,000 is received at MCGRI.  All Payments due to the University of Minnesota will be coordinated by MCGRI according to the terms stated in “Agreement For Joint Ownership and Commercialization for Case 023-07”, between MCG and the University of Minnesota.
This present amendment shall hereby be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.

						
	MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE

	NEWLINK GENETICS

	By /s/Betty Aldridge
Name: Betty Aldridge
Title: Executive Director
Date: 2/13/07
	By: /s/Nicholas N. Vahanian
Name: Nicholas N. Vahanian
Title: Chief Medical and Operations Office
Date: 2/6/07Document

Exhibit 10.1.4

LICENSE AGREEMENT AMENDMENT

The following is an amendment to Exhibit A of the License Agreement between Medical College of Georgia and NewLink Genetics previously executed on September 13th, 2005. The purpose of this amendment is to explicitly list patent applications filed previously to the execution of this Agreement as continuations of Case # 009-03, and which were unintentionally ommited in the original Exhibit A. These missing patent applications are: Provisional US 60/538,647 and Non-Provisional Patents US 10/780,150 and US 10/780,797.

The present amendment should be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.

						
	MEDICAL COLLEGE OF GEORGIA
 
RESEARCH INSTITUTE	LICENSEE:

NEWLINK GENETICS
	By:  /s/ Betty Aldridge
	By:  /s/ Nicholas Vahanian

	Name:   Betty Aldridge
 Executive Director
  MCG Research Institute  
	Name:  Nicholas Vahanian

	Title:  
	Title: Chief Medical & Operations Officer 

	Date: 3/28/06   
	Date: 3/28/06              

		
		

EXHIBIT A
LICENSED PATENTS
						
	[Case #007-98
	“Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. Patent No. 6,451,840 Inventors: D. Munn and A. Mellor

	Case #007-98 Div1
	“Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. Patent No. 6,482,416 Inventors: D. Munn and A. Mellor

	Case #007-98 Div2
	“Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. non-Provisional/Regular Patent Application 10/112,362 Inventors: D. Munn and A. Mellor

	Case #011-98
	High Affinity Tryptophan Transporter” U.S. Patent No. 6,395,876 Inventors: D. Munn and A. Mellor

	Case #011-02
	“Antigen-Presenting Cell Populations and Their Use as Reagents for Enhancing of Reducing Immune Tolerance” U.S. non-Provisional/Regular Patent Application 10/121,909 Inventors: D. Munn and A. Mellor

	Case #003-03
	“Chemokine Receptor Antagonists as Therapeutic Agents” U.S. non-Provisional/Regular Patent Application 10/660,131 Inventors: D. Munn, A. Mellor and S. Peiper

	Case #009-03
	“Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase” U.S. Provisional Patent Application 60/459,489 Inventors: D. Munn and A. Mellor

	Case #009-03
	“Inhibitors of Indoleamine-2,3-Dioxygenase and Methods of Use” U.S. Provisional Patent Application 60/538,647 Inventors: D. Munn and A. Mellor

	Case #009-03
	“Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase” U.S. Non-Provisional/Regular Patent Application 10/780,150 Inventors: D. Munn and A. Mellor

	Case #009-03
	“Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities” U.S. Non-Provisional/Regular Patent Application 10/780,797 Inventors: D. Munn and A. Mellor]Document

Exhibit 10.1.5

AMENDMENT TO LICENSE AGREEMENT

        This Amendment to License Agreement (“Amendment”) is effective as of July 10, 2014 (the “Amendment Effective Date”), by and between Georgia Regents Research Institute, Inc. (formerly known as Georgia Health Sciences University Research Institute, Inc. which was formerly known as Medical College of Georgia Research Institute, Inc.) (“GRRI”) and NewLink Genetics Corporation (“NewLink”).  GRRI and NewLink are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

        WHEREAS, GRRI and NewLink are parties to that certain License Agreement dated as of September 13, 2005, and amended on March 28, 2006, April 27, 2006, February 13, 2007 and July 12, 2013 (the “Agreement”); and

        WHEREAS, the Parties desire to amend the Agreement in accordance with Section 14.8 thereof; 

        NOW THEREFORE, in consideration of the premises and mutual covenants contained in this Amendment, the Parties agree as follows:

1.All references in the Agreement to MCGRI or GHSURI are hereby deemed references to GRRI.
2.Each reference to “Licensee” in Section 1.12 (the definition of “Net Selling Price”) that is not part of the phrase “Licensee or its Affiliate” is hereby deleted and replaced with “Licensee or its Affiliate”.
3.The second and third sentences of Section 2.5 are hereby deleted and replaced with the following:
LICENSEE acknowledges that, in accordance with Public Law 96-517 and other statutes, regulations, and Executive Orders as now exist or may be amended or enacted, the United States government may have certain rights in the Licensed Patents and Licensed Technology.  LICENSEE shall take all action necessary to enable GRRI to satisfy its obligations, if any, under any federal law relating to the Licensed Patents or Licensed Technology.
4.The following language shall be inserted as a new Section 2.7:
2.7 Transfer of Intellectual Property Rights Between Affiliates.  LICENSEE and each Affiliate of LICENSEE may transfer all or part of its right and license under the Licensed Patents and Licensed Technology pursuant to Section 2.1 to, as applicable, LICENSEE or another Affiliate of LICENSEE.  For clarity, this Section 2.7 authorizes LICENSEE and its Affiliates to enter into agreements necessary to, as between LICENSEE and its Affiliates, consolidate the rights licensed to LICENSEE and its Affiliates (collectively, pursuant to Section 2.1 of this Agreement) solely in LICENSEE or a single Affiliate of LICENSEE. LICENSEE or an Affiliate shall provide to GRRI a copy of any such agreement or other document reflecting a transfer under this provision and any amendment thereto, including all attachments, exhibits, and/or addendums, within 30 days of execution; provided, however, such copies to GRRI may be redacted to exclude confidential information of the applicable Affiliate or of LICENSEE to the extent not relevant to GRRI, but such copies shall not be redacted to the extent that it impairs GRRI’s ability to ensure compliance with this Agreement.
5.The first sentence of Section 4.2 is hereby deleted and replaced with the following: 
LICENSEE shall pay GRRI twenty five percent (25%) of any fees or payments or remuneration paid to LICENSEE or an Affiliate of LICENSEE by a Sublicensee in relation to this License and
-1-
         

 for rights to all or part of the Licensed Patents other than: research funding (including purchase price of Licensed Products to be used by Sublicensee in connection with research and development activities), equity, loans, or patent costs or fee reimbursements.
6.Section 4.3 is hereby deleted and replaced with the following:
As partial consideration for the license granted to LICENSEE under this Agreement, LICENSEE shall pay GRRI the following royalties based on the Net Selling Price of the applicable Licensed Products sold by LICENSEE or an Affiliate of LICENSEE:
        Therapeutics (cancer/non-cancer)   3%
        Diagnostics     4%
        Reagents/Lab Consumables   5%
Notwithstanding the foregoing, if LICENSEE or an Affiliate of LICENSEE is required to pay a royalty under a patent license from any third party in order to sell a Licensed Product, then LICENSEE may reduce the royalty otherwise payable to GRRI on the Net Selling Price of such Licensed Product by 50% of the royalty amounts paid to such third party; provided, however, that in no event will the royalty payable to GRRI hereunder with respect to such Licensed Product be reduced to less than 1.5%.  Royalties shall be payable on a Licensed Product-by-Licensed Product and country-by-country basis from first commercial sale of a Licensed Product in a country until the expiration of the last to expire valid claim of the Licensed Patents claiming the manufacture, use or sale of such Licensed Product in such country.
7.Section 2.2 is hereby deleted and replaced with the following: 
2.2 Sublicensing. Licensee and its Affiliates may sublicense to one or more third parties the rights granted under this Agreement, subject to the prior approval of GRRI, not to be unreasonably withheld or delayed. If this Agreement is terminated for any reason, any sublicenses granted shall remain in full force and effect and be directly enforceable by GRRI. Licensee or an Affiliate shall provide to GRRI a copy of any such sublicense and any amendment thereto, including all attachments, exhibits, and/or addendums, within 30 days of execution; provided, however, such copies to GRRI may be redacted to exclude confidential information of the applicable Sublicensee or of LICENSEE to the extent not relevant to GRRI, but such copies shall not be redacted to the extent that it impairs GRRI’s ability to ensure compliance with this Agreement.      
8.The first sentence of Section 9.2 shall be deleted and replaced with the following language:
The following shall be treated as confidential information of Licensee and shall not be disclosed to any third party without the prior written consent of Licensee: (i) all reports provided to GRRI pursuant to this Agreement and (ii) all documents provided to GRRI pursuant to Section 2.2 and Section 2.7 of this Agreement.
9.Except as expressly amended hereby, the terms and conditions of the Agreement shall remain unchanged and in full force and effect.  In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall govern.  The amendments made herein shall be effective as of the Amendment Effective Date.  Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement.  For clarity, any cross-references to Agreement Sections refer to those Agreement Sections as amended by this Amendment.  This Amendment may be executed in counterparts, each of which shall be deemed an original but all of which shall be considered one and the same instrument.
[Signature Page Follows]

-2-
         

IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly authorized officers as of the date set forth above.

						
	

	

						
	Georgia Regents Research Institute, Inc.

By:/s/ Sarah J. White  
Name: Sarah J. White
Title: Executive Director
        Georgia Regents Research Institute, Inc.
        7-10-2014

	NewLink Genetics Corporation

By: /s/ Gordon Link  
Name: Gordon Link
Title: CFO

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]